Brainstorm cell therapeutics summarizes key messages from its participation as expert speakers in an invited presentation and panel discussion at the 2023 als drug development summit

-  presentation by co-ceo stacy lindborg, ph.d., held at 2023 als drug development summit -  summit focused on transforming translational tools to accelerate future als approvals new york , may 19, 2023 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, joined an international audience of patient advocacy groups, physicians, research organizations, industry representatives, key thought leaders and decision makers dedicated to als research, at the 2023 als drug development summit, through an invited presentation and panel discussion on may 17 and 18, 2023.
BCLI Ratings Summary
BCLI Quant Ranking